Clinical Trial: NCT03755739
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | Second Affiliated Hospital of Guangzhou Medical University |
| Information Provided By: | Second Affiliated Hospital of Guangzhou Medical University |
| Last Update Posted: | 2024-06-25 |
Study Overview
Brief Summary
This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences.
Official Title
A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors
Conditions
Hepatocarcinoma, Lung Cancer, Melanoma, Renal Cancer, Head and Neck Cancer, Pancreas Cancer, Ovarian Cancer, Colo-rectal Cancer, Cervical Cancer, Breast Cancer
Intervention / Treatment
- Drug: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy
Other Study ID Numbers
- ZZITICI-004
Start Date (Actual)
2018-11-01
Primary Completion Date (Estimated)
2033-11-01
Study Completion Date (Estimated)
2036-11-01
Enrollment (Estimated)
200
Study Type
Interventional
Phase
Phase 2, Phase 3
| Lead Sponsor: | Second Affiliated Hospital of Guangzhou Medical University |
| Information Provided By: | Second Affiliated Hospital of Guangzhou Medical University |
| Last Update Posted: | 2024-06-25 |
Study Overview
Brief Summary
This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences.
Official Title
A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors
Conditions
Hepatocarcinoma, Lung Cancer, Melanoma, Renal Cancer, Head and Neck Cancer, Pancreas Cancer, Ovarian Cancer, Colo-rectal Cancer, Cervical Cancer, Breast Cancer
Intervention / Treatment
- Drug: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy
Other Study ID Numbers
- ZZITICI-004
Start Date (Actual)
2018-11-01
Primary Completion Date (Estimated)
2033-11-01
Study Completion Date (Estimated)
2036-11-01
Enrollment (Estimated)
200
Study Type
Interventional
Phase
Phase 2, Phase 3